Dengue
Conditions
Interventions
Normal group:none
Severe disease group:None
Sponsors
The First People's Hospital of Foshan
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: Voluntarily signed informed consent; Age= 18 years old, male or female; Including recent dengue fever cases in dengue-endemic areas, places of residence or work, fever, muscular and osteoarthralgia, headache and rash, decreased white blood cell and/or platelet count, and positive dengue virus-specific IgM antibodies in a single serum dose; The laboratory confirmation criteria are that the clinical case of dengue fever is met, the dengue virus nucleic acid is positive, or the dengue virus nonstructural protein 1 (NS1) antigen is positive, or the virus is isolated, or the serum specific IgG antibody titer in the convalescent phase is more than 4 times higher than that in the acute phase; Subject is voluntary and able to comply with all requirements specified in the study protocol.
Exclusion criteria
Exclusion criteria: Suspected focal infection Subject has other pre-existing medical conditions that may preclude compliance with the various evaluation plans in the treatment protocol, or may interfere with the observation of the efficacy or safety of this study (e.g., current malignancy, uncontrolled seizures, severe psychiatric illness, active tuberculosis currently being treated, etc.); Patients who are judged by the investigator to be unsuitable to participate in this trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical features, viral molecular features, immunological features, and differences; | — |
Secondary
| Measure | Time frame |
|---|---|
| Chronic fatigue syndrome, musculoskeletal disorders, anxiety, depression, or cognitive impairment;Safety indicators; | — |
Countries
China
Contacts
Public ContactBai Honglian
The First People's Hospital of Foshan
Outcome results
None listed